Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lerodalcibep→

Lerodalcibep Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2250073-78-8
Molecular formula
C3427H5324N908O1045S40
Molecular weight
77247.08 g/mol
Drug class
PCSK9 inhibitorrecombinant fusion protein lipid-lowering biologic
Mechanism of action
Binds proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity and prevents PCSK9 binding to hepatic LDL receptors, reducing receptor degradation and increasing LDL-receptor availability to clear LDL cholesterol from the blood.
Indications / reported uses
  • Adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, under the US FDA LEROCHOL indication (approved 12 December 2025)

Sources: US FDA prescribing information — LEROCHOL, revised August 2026 · NLM DailyMed — LEROCHOL (lerodalcibep-liga) · FDA Drug Trials Snapshot — LEROCHOL · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lerodalcibep Environmental Risk Assessment (ERA) (the Lerodalcibep ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.